Tenon Medical, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TNON research report →
Range $2.25 – $2.25
Price Chart
About the company
Tenon Medical, Inc. , a medical device company, engages in the development of implant for the treatment of severe lower back pain in the United States. The company offers Catamaran SI-Joint Fusion System, an invasive approach to the sacroiliac joint (SI Joint) using a titanium implant for treatment of the most common types of SI Joint disorders that cause lower back pain.
- CEO
- Steven Foster
- IPO
- 2022
- Employees
- 26
- HQ
- Los Gatos, CA, US
Get TickerSpark's AI analysis on TNON
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.41M
- P/E
- -0.02
- Fwd P/E
- 3.59
- PEG
- -0.00
- P/S
- 0.08
- P/B
- 0.12
- EV/EBITDA
- 0.43
- Div Yield
- 0.00%
- Gross Margin
- 66.35%
- Op Margin
- -225.74%
- Net Margin
- -303.49%
- ROE
- -470.92%
- ROIC
- -100.25%
Latest fiscal year · YoY change
- Revenue
- $3.94M+20.4%
- Gross Profit
- $2.36M+37.8%
- Op Income
- $-12,792,000
- Net Income
- $-12,556,000+8.2%
- EPS
- $-59.50+84.9%
- OCF Growth
- -8.8%
- FCF Growth
- -9.5%
- 52W High
- $40.95
- 52W Low
- $0.89
- 50D MA
- $2.69
- 200D MA
- $14.87
- Beta
- 1.43
- RSI (14)
- 21
- Avg Volume
- 5.46M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Tenon Medical posted stronger third-quarter revenue and gross margin growth while cleaning up its balance sheet and pushing several new product launches forward.· November 12, 2026
- Q3 revenue rose to $1.4 million, up 22% year over year and 12% sequentially.
- Gross profit was $1.0 million with gross margin of 66.3%, helped by higher revenue and lower Catamaran cost of sales.
- Operating loss improved to $3.1 million from $3.4 million a year ago, while operating expenses fell sequentially.
- The company raised about $15.6 million in gross proceeds in the quarter and repaid its convertible notes in full ahead of maturity.
- Management highlighted momentum in Catamaran and Symmetry adoption, plus upcoming product launches including Quick Step and a Symmetry Plus implant enhancement.
Third-quarter revenue was $1.4 million, up 22% from $1.2 million a year ago and up 12% sequentially. Gross profit was $1.0 million, up 23% year over year, and gross margin was 66.3% versus 65.9% in the prior-year period. Operating expenses were $4.0 million, down from $4.2 million a year ago, and loss from operations improved to $3.1 million from $3.4 million. Net loss was $6.6 million, or $5.39 per share, compared with a net loss of $3.3 million, or $14.17 per share, a year ago; per-share figures reflect the 1-for-35 reverse split. For the first nine months, revenue was $4.1 million, up 66% from $2.5 million, and gross profit was $2.7 million versus $1.3 million with gross margin of 66.2% versus 54.4%. The company did not provide formal next-quarter or full-year financial guidance, but said it expects gross margin to continue expanding as revenue grows and fixed costs are better absorbed.
Steven Foster framed the quarter as a mix of commercial progress, product development execution, and balance-sheet repair. He emphasized that Catamaran and Symmetry adoption is expanding, physician training remains a key indicator, and the company is moving into a broader commercial phase with a new chief revenue officer and plans to add sales reps and distributor partners. He also struck an optimistic tone on the pipeline, citing the full launch of the Symmetry Plus lateral screw, alpha cases for Quick Step, and additional launches planned over the coming quarters.
Kevin Williamson focused on the drivers of revenue and margin improvement, saying Q3 gross margin benefited from higher revenue absorbing fixed costs and from improved Catamaran per-procedure costs after the 510(k) clearance that reclassified certain instruments to reusable status. He noted operating expenses totaled $4.0 million in the quarter, below $4.2 million a year ago, and that the quarter’s higher net loss was mainly due to noncash items, including $3.1 million of warrant expense and $700 thousand of noncash interest expense. He also highlighted liquidity and capital actions: approximately $15.6 million in gross proceeds raised during the quarter, full repayment of roughly $5.16 million of senior convertible notes ahead of the 09/11/2026 maturity, no outstanding debt at quarter end, and about $7.1 million of ATM availability after quarter end.
There were no analyst questions on the call, as the operator noted there were no further questions. As a result, management did not need to address follow-up concerns live beyond the prepared remarks. The closest thing to guidance was commentary that momentum should continue through recent and upcoming salesforce expansion, stronger physician and distributor engagement, future product launches, and continued gross-margin expansion as revenue scales.
The bull case from the call is that Tenon showed real top-line acceleration, improving gross margin, and better operating leverage while also simplifying its capital structure. Management sounded confident that new products, broader commercial coverage, and continued physician training can sustain momentum into 2027.
The main risks are that the company is still posting sizable losses, including a $6.6 million net loss in Q3, and it did not provide formal revenue or earnings guidance. Growth also depends on continued commercial execution and successful launches of products that are still in development, while cash remains limited despite the recent capital raise.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 89.7%
- Shares Outstanding
- 496.46K
- Float Shares
- 445.26K
of shares held by institutions
23 13F filers
Buy/sell ratio 0.82. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 5 ETFs
Biggest fund positions in TNON by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Batton Thomas Henry Jr | other | 0 |
| Sep 9, 26 | HRT FINANCIAL LP | sell | 9,948 |
| Sep 9, 26 | HRT FINANCIAL LP | sell | 50,395 |
| Sep 9, 26 | HRT FINANCIAL LP | buy | 39,508 |
| Sep 10, 26 | HRT FINANCIAL LP | sell | 65,582 |
| Sep 10, 26 | HRT FINANCIAL LP | buy | 31,227 |
| Sep 10, 26 | HRT FINANCIAL LP | buy | 28,267 |
| Sep 10, 26 | HRT FINANCIAL LP | buy | 8,431 |
| Sep 8, 26 | HRT FINANCIAL LP | buy | 707 |
| Sep 8, 26 | Williamson Kevin | other | 30 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TNON coverage
Recent articles, reports, and earnings notes.
No research on TNON yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TNON report →Tenon Medical, Inc. (TNON) Q3 2026 Earnings Call Prepared Remarks Transcript
seekingalpha.com · Nov 12
Tenon Medical(R) Adds Eight New Patents Issued by the United States Patent and Trademark Office Through Q3 2026
accessnewswire.com · Oct 15
Tenon Medical, Inc. (NASDAQ:TNON) Sees Large Drop in Short Interest
defenseworld.net · Oct 12
Tenon(R) Medical Announces Full Commercial Launch of the SImmetry(R)+ SI Joint Fusion 3D Printed Lateral Screw Following Successful Alpha Launch
accessnewswire.com · Sep 30
WallachBeth Capital Announces Closing of Tenon Medical Warrant Inducement Offering for Aggregate Gross Proceeds of Approximately $2,872,338
prnewswire.com · Sep 14
Tenon Medical Announces Closing of Warrant Inducement Offering for Aggregate Gross Proceeds of Approximately $2,872,338
accessnewswire.com · Sep 14
WallachBeth Capital Announces Tenon Medical Warrant Inducement for Gross Proceeds of Approximately $2,872,338
prnewswire.com · Sep 11
Tenon Medical Announces Warrant Inducement for Aggregate Gross Proceeds of Approximately $2,872,338
accessnewswire.com · Sep 11
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.